Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab
✍ Scribed by Jens Chemnitz; Andreas Draube; Christof Scheid; Peter Staib; Armin Schulz; Volker Diehl; Dietmar Söhngen
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 155 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Idiopathic thrombocytopenic purpura (ITP) is refractory to initial treatment (steroids and splenectomy) in 25 to 30% of patients. These patients have a significant risk of fatal hemorrhage. Two patients with ITP refractory to multiple interventions and severe depression of platelet counts responded
Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp
## Abstract The mainstay of treatment for thrombotic thrombocytopenic purpura (TTP) is plasma exchange (PE), but the role of splenectomy is still undefined. The records of all patients with TTP at a single center over a 20‐year period were retrospectively reviewed. Response to plasma exchange was d
## Unusual Behavior of Primary Tonsillary Lymphoma To the Editor: Primary tonsillary lymphoma accounts for less than 1% of head and neck malignancies. Tonsillectomy is used to mainly establish the diagnosis and can be performed for localized small lesions. In general, the patients are treated by c